Lantern Pharma【LTRN】株式ニュース

名称	銘柄コード	市場	種別
Lantern Pharma Inc	LTRN	NASDAQ	普通株式

	前日比	前日比 %	現在値	時刻
	-0.08	-1.71%	4.61	04:21:49

始値	安値	高値	終値	前日終値
4.61	4.32	4.61		4.69

この銘柄の詳細情報 »

最新ニュース

日付	時間	ソース	タイトル
2024/6/18	05:15	EDGAR2	Form 8-K - Current report
2024/6/12	20:30	BW	Lantern Pharma Receives Certificate of Patent from Japanese..
2024/6/11	13:16	EDGAR2	Form EFFECT - Notice of Effectiveness
2024/5/25	05:09	EDGAR2	Form 8-K - Current report
2024/5/25	05:08	EDGAR2	Form S-8 - Securities to be offered to employees in employee..
2024/5/25	05:06	EDGAR2	Form S-3 - Registration statement under Securities Act of..
2024/5/13	14:30	BW	Oregon Therapeutics et Lantern Pharma lancent une..
2024/5/10	05:05	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/5/10	05:02	BW	Lantern Pharma Reports First Quarter 2024 Financial Results..
2024/5/06	16:00	BW	Oregon Therapeutics & Lantern Pharma Launch Strategic AI..
2024/5/02	20:30	BW	Lantern Pharma to Report First Quarter 2024 Operating &..
2024/4/24	21:00	BW	Lantern Pharma Launches “Webinar Wednesdays” Featuring..
2024/4/22	21:12	BW	Lantern Pharma Receives Regulatory Approval to Expand..
2024/3/19	05:02	BW	Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023..
2024/3/18	20:12	IHMARKETNEWS	Anticipation Builds on Wall Street for Federal Reserve’s..
2024/3/15	21:00	BW	Lantern Pharma Announces Initial Patients Dosed in..
2024/3/11	20:30	BW	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023..
2024/3/05	22:01	BW	Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st..
2024/3/04	22:01	BW	Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion..
2024/3/01	11:54	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/2/15	22:01	BW	Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate)..
2024/1/20	06:30	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/1/17	21:30	BW	Starlight Therapeutics, a Subsidiary of Lantern Pharma..
2023/12/30	06:05	EDGAR2	Form 8-K - Current report
2023/12/01	20:02	EDGAR2	Form SC 13D/A - General statement of acquisition of..
2023/12/01	20:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2023/11/30	22:00	BW	FDA Grants Lantern Pharma Orphan Drug Designation for Drug..
2023/11/25	06:05	EDGAR2	Form 8-K - Current report
2023/11/09	06:05	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/09	06:05	EDGAR2	Form 8-K - Current report
2023/11/09	06:01	BW	Lantern Pharma Reports Third Quarter 2023 Financial Results..
2023/11/01	21:00	BW	Lantern Pharma to Report Third Quarter 2023 Operating &..
2023/10/21	06:25	EDGAR2	Form 8-K - Current report
2023/10/10	21:00	BW	Lantern Pharma to Present at the ThinkEquity Conference on..
2023/10/03	21:00	BW	Lantern Pharma Announces Publication in Clinical Cancer..
2023/9/25	21:30	BW	Lantern Pharma Announces First Patient Dosed in the Phase 1..
2023/9/18	22:00	BW	Lantern Pharma Receives IND Clearance from FDA Enabling..
2023/8/31	21:00	BW	Lantern Pharma to Present Data Highlighting the Anti-Tumor..
2023/8/28	21:00	BW	Lantern Pharma Expands AI Capabilities of RADR® Platform to..
2023/8/14	21:30	BW	Lantern Pharma Receives Notice of US Patent Allowance for..
2023/8/10	05:05	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/10	05:05	EDGAR2	Form 8-K - Current report
2023/8/10	05:01	BW	Lantern Pharma Reports Second Quarter 2023 Financial Results..
2023/8/02	21:00	BW	Lantern Pharma to Report Second Quarter 2023 Operating &..
2023/7/17	21:00	BW	Lantern Pharma to Participate and Present at Multiple..
2023/6/26	21:30	BW	Oncotarget Publishes New Data by Lantern Pharma, an AI..